AQST — Aquestive Therapeutics Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$5.31
+$0.07 (+1.34%)
Aquestive Therapeutics Inc (AQST) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Daniel Barber, based in 30 Technology Drive, Warren, NJ, United States, 07059, with about 147 employees. Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Latest reported AQST revenue for 2025-09-30 was $12.8M. Net income was -$15.4M. Revenue was up 28.0% from 2025-06-30 to 2025-09-30. AQST currently screens at market cap $493.0M.
Use this AQST page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AQST quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AQST SEC filings page. Lician reads the product cache first so this HTML stays unique to Aquestive Therapeutics Inc even when a live quote feed is slow.
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Key Statistics
Market Cap
$493.02M
Volume
1.79M
Previous Close
$4.80
Day Range
$4.72 – $5.08
EPS
-$0.51
Revenue
$57.56M
Net Income
-$44.14M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+13.8%
Profit Margin
-76.7%
Employees
147
AQST Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $57.56M | $50.58M | $47.68M | $50.83M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$44.14M | -$7.87M | -$54.41M | -$70.54M |
| EPS (Diluted) | -$0.51 | -$0.13 | -$1.12 | -$1.85 |
Total Assets
$101.42M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$35.76M
Free Cash Flow
$0.00
Aquestive Therapeutics Inc Company Information
- CEO, President & Director
- Daniel Barber
- Headquarters
- 30 Technology Drive, Warren, NJ, United States, 07059
- Website
- www.aquestive.com
- Phone
- 908 941 1900
- IPO / Founded
- 2018-07-25
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic